Larina Tzu-Wei Shen
Larina Tzu-Wei Shen has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
Satoshi Matsusaka
Department of Clinical Research and Regional Innovation, Faculty of Medicine University of Tsukuba Tsukuba Japan
3 shared publications- Satoshi Matsusaka
Department of Clinical Research and Regional Innovation, University of Tsukuba, Tsukuba, Japan
3 shared publications - Afsana Islam
OPTIEUM BIOTECHNOLOGIES, Toon 791-0204, Ehime, Japan
2 shared publications - Daiki Fujita
OPTIEUM BIOTECHNOLOGIES, Toon 791-0204, Ehime, Japan
2 shared publications - Kazumasa Oya
Department of Dermatology, Institute of Medicine University of Tsukuba Ibaraki Japan
2 shared publications - Kazunobu Ohnuki
Division of Cancer Immunotherapy, Exploratory Oncology Research and Clinical Trial Center, National Cancer center, Kashiwa 277-8577, Japan, Japan
2 shared publications
Latest Publications
- Open Access
- 26 October 2026
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 48 (11) , 1115
EPHB4-Targeted CAR-T Cells Demonstrate Antitumor Activity in an Orthotopic Tongue PDX Model of Oral Squamous Cell Carcinoma
Oral squamous cell carcinoma (OSCC) remains associated with poor outcomes and functional impairment despite multimodal treatment, underscoring the need for effective and less invasive therapeutic strategies. Ephrin type-B receptor 4 (EPHB4) is frequently expressed on OSCC cells and represents a potential target for chimeric antigen receptor (CAR)-T cell therapy. In this study, we evaluated the antitumor activity of EPHB4-targeted CAR-T cells (131CAR) using in vitro cytotoxicity assays against the OSCC cell line HSC-4 and an orthotopic tongue patient-derived xenograft (PDX) model established from an OSCC tumor (OC-15) in NOD scid gamma (NSG) mice. Flow cytometry confirmed EPHB4 expression in HSC-4 cells (~90%) and OC-15-derived tumor cells (~68%). In vitro assays demonstrated effector-to-target-ratio-dependent cytotoxicity of 131CAR against HSC-4 cells. In the main in vivo experiment, intratumoral administration of 131CAR suppressed tumor growth and significantly reduced the cytokeratin-defined carcinoma area compared with control groups. Digital pathology further showed a reduced proportion of EPHB4-positive area within the residual carcinoma and increased accumulation of human CD8+ cells in 131CAR-treated tumors. These findings indicate that EPHB4-targeted CAR-T cells exert antitumor activity in an orthotopic OSCC model and support further preclinical evaluation of this therapeutic approach in anatomically relevant settings.
- 26 October 2026
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 48 (11) , 1115
Open AccessEPHB4-Targeted CAR-T Cells Demonstrate Antitumor Activity in an Orthotopic Tongue PDX Model of Oral Squamous Cell Carcinoma
Oral squamous cell carcinoma (OSCC) remains associated with poor outcomes and functional impairment despite multimodal treatment, underscoring the need for effective and less invasive therapeutic strategies. Ephrin type-B receptor 4 (EPHB4) is frequently expressed on OSCC cells and represents a potential target for chimeric antigen receptor (CAR)-T cell therapy. In this study, we evaluated the antitumor activity of EPHB4-targeted CAR-T cells (131CAR) using in vitro cytotoxicity assays against the OSCC cell line HSC-4 and an orthotopic tongue patient-derived xenograft (PDX) model established from an OSCC tumor (OC-15) in NOD scid gamma (NSG) mice. Flow cytometry confirmed EPHB4 expression in HSC-4 cells (~90%) and OC-15-derived tumor cells (~68%). In vitro assays demonstrated effector-to-target-ratio-dependent cytotoxicity of 131CAR against HSC-4 cells. In the main in vivo experiment, intratumoral administration of 131CAR suppressed tumor growth and significantly reduced the cytokeratin-defined carcinoma area compared with control groups. Digital pathology further showed a reduced proportion of EPHB4-positive area within the residual carcinoma and increased accumulation of human CD8+ cells in 131CAR-treated tumors. These findings indicate that EPHB4-targeted CAR-T cells exert antitumor activity in an orthotopic OSCC model and support further preclinical evaluation of this therapeutic approach in anatomically relevant settings.
- Open Access
- 4 March 2026
- Published by MDPI AG in Preprints.org
EPHB4-Targeted CAR-T Cells Demonstrate Potent Antitumor Activity in an Orthotopic Tongue PDX Model of Oral Squamous Cell Carcinoma
Oral squamous cell carcinoma (OSCC) remains associated with poor outcomes and functional impairment despite multimodal treatment, underscoring the need for effective and less invasive therapeutic strategies. Ephrin type-B receptor 4 (EPHB4) is frequently expressed on OSCC cells and represents a potential target for chimeric antigen receptor (CAR)-T cell therapy. In this study, we evaluated the antitumor activity of EPHB4-targeted CAR-T cells (131CAR) using in vitro cytotoxicity assays against the OSCC cell line HSC-4 and an orthotopic tongue patient-derived xenograft (PDX) model established from an OSCC tumor (OC-15) in NOD scid gamma (NSG) mice. Flow cytometry confirmed EPHB4 expression in HSC-4 cells (~90%) and OC-15-derived tumor cells (~68%). In vitro assays demonstrated effector-to-target ratio–dependent cytotoxicity of 131CAR against HSC-4 cells. In vivo, both intratumoral and intravenous administration of 131CAR significantly reduced tumor burden compared to control groups, with greater tumor reduction observed following intratumoral delivery. Immunohistochemistry revealed infiltration of human CD8⁺ cells and decreased tumor area in treated tumors, and digital pathology analysis corroborated the reduced tumor area. These findings indicate that EPHB4-targeted CAR-T cells exert antitumor activity in an orthotopic OSCC model and suggest that local administration may enhance therapeutic efficacy in anatomically relevant settings.
- 4 March 2026
- Published by MDPI AG in Preprints.org
Open AccessEPHB4-Targeted CAR-T Cells Demonstrate Potent Antitumor Activity in an Orthotopic Tongue PDX Model of Oral Squamous Cell Carcinoma
Oral squamous cell carcinoma (OSCC) remains associated with poor outcomes and functional impairment despite multimodal treatment, underscoring the need for effective and less invasive therapeutic strategies. Ephrin type-B receptor 4 (EPHB4) is frequently expressed on OSCC cells and represents a potential target for chimeric antigen receptor (CAR)-T cell therapy. In this study, we evaluated the antitumor activity of EPHB4-targeted CAR-T cells (131CAR) using in vitro cytotoxicity assays against the OSCC cell line HSC-4 and an orthotopic tongue patient-derived xenograft (PDX) model established from an OSCC tumor (OC-15) in NOD scid gamma (NSG) mice. Flow cytometry confirmed EPHB4 expression in HSC-4 cells (~90%) and OC-15-derived tumor cells (~68%). In vitro assays demonstrated effector-to-target ratio–dependent cytotoxicity of 131CAR against HSC-4 cells. In vivo, both intratumoral and intravenous administration of 131CAR significantly reduced tumor burden compared to control groups, with greater tumor reduction observed following intratumoral delivery. Immunohistochemistry revealed infiltration of human CD8⁺ cells and decreased tumor area in treated tumors, and digital pathology analysis corroborated the reduced tumor area. These findings indicate that EPHB4-targeted CAR-T cells exert antitumor activity in an orthotopic OSCC model and suggest that local administration may enhance therapeutic efficacy in anatomically relevant settings.
- 3 March 2024
- Published by Wiley in The Journal of Dermatology
- Vol. 51 (6) , 807-815
Soluble PD‐L1 predicts tumor response and immune‐related adverse events in patients with advanced melanoma treated with anti–PD‐1 antibodies
Immune checkpoint inhibitors (ICIs) bring prognostic benefits to patients with malignancies. However, there is a substantial number of patients whose lesions are not improved by ICIs. In addition, ICIs may cause immune‐related adverse events (irAEs), which could lead to an unfavorable prognosis with fatal consequences. Therefore, we conducted a retrospective study to evaluate the utility of circulating sPD‐L1 (soluble programmed cell death 1 ligand 1) as a biomarker in patients with advanced melanoma treated with anti–PD‐1 (programmed cell death 1 protein) antibodies. Sera from 31 consecutive patients were prospectively collected before and after anti–PD‐1 antibody treatment and the serum level of sPD‐L1 was evaluated. We found that high sPD‐L1 levels before treatment were associated with better prognosis, and this association was observed only in patients with a low tumor burden. We also found that sPD‐L1 levels were elevated in patients who developed severe irAEs after treatment, and the patients with severe irAEs had significantly higher fluctuations in sPD‐L1 (delta sPD‐L1) than those without severe irAEs. Our study suggests that serum sPD‐L1 level is a useful biomarker to predict tumor response and irAE development in patients with advanced melanoma treated with anti–PD‐1 antibodies.
- 3 March 2024
- Published by Wiley in The Journal of Dermatology
- Vol. 51 (6) , 807-815
Soluble PD‐L1 predicts tumor response and immune‐related adverse events in patients with advanced melanoma treated with anti–PD‐1 antibodies
Immune checkpoint inhibitors (ICIs) bring prognostic benefits to patients with malignancies. However, there is a substantial number of patients whose lesions are not improved by ICIs. In addition, ICIs may cause immune‐related adverse events (irAEs), which could lead to an unfavorable prognosis with fatal consequences. Therefore, we conducted a retrospective study to evaluate the utility of circulating sPD‐L1 (soluble programmed cell death 1 ligand 1) as a biomarker in patients with advanced melanoma treated with anti–PD‐1 (programmed cell death 1 protein) antibodies. Sera from 31 consecutive patients were prospectively collected before and after anti–PD‐1 antibody treatment and the serum level of sPD‐L1 was evaluated. We found that high sPD‐L1 levels before treatment were associated with better prognosis, and this association was observed only in patients with a low tumor burden. We also found that sPD‐L1 levels were elevated in patients who developed severe irAEs after treatment, and the patients with severe irAEs had significantly higher fluctuations in sPD‐L1 (delta sPD‐L1) than those without severe irAEs. Our study suggests that serum sPD‐L1 level is a useful biomarker to predict tumor response and irAE development in patients with advanced melanoma treated with anti–PD‐1 antibodies.
- Open Access
- 10 January 2023
- Published by Royal Society of Chemistry (RSC) in Lab on a Chip
- Vol. 23 (6) , 1561-1575
Virtual-freezing fluorescence imaging flow cytometry with 5-aminolevulinic acid stimulation and antibody labeling for detecting all forms of circulating tumor cells
Heterogeneous clusters of cancer cells and leukocytes in blood were visualized by combining high-throughput and high-sensitivity fluorescence imaging flow cytometry with 5-aminolevulinic acid stimulation.
- 10 January 2023
- Published by Royal Society of Chemistry (RSC) in Lab on a Chip
- Vol. 23 (6) , 1561-1575
Open AccessVirtual-freezing fluorescence imaging flow cytometry with 5-aminolevulinic acid stimulation and antibody labeling for detecting all forms of circulating tumor cells
Heterogeneous clusters of cancer cells and leukocytes in blood were visualized by combining high-throughput and high-sensitivity fluorescence imaging flow cytometry with 5-aminolevulinic acid stimulation.
- Open Access
Label-free drug response evaluation of human derived tumor spheroids using three-dimensional dynamic optical coherence tomography
We demonstrate label-free drug response evaluations of human breast (MCF-7) and colon (HT-29) cancer spheroids via dynamic optical coherence tomography (OCT). The MCF-7 and HT-29 spheroids were treated with paclitaxel (PTX, or Taxol) and the active metabolite of irinotecan (SN-38), respectively. The drugs were applied using 0 (control), 0.1, 1, and 10 uM concentrations with treatment times of 1, 3, and 6 days. The samples were scanned using a repeated raster scan protocol and two dynamic OCT algorithms, logarithmic intensity variance (LIV) and late OCT correlation decay speed (OCDSl) analyses, were applied to visualize the tissue and cellular dynamics. Different drug response patterns of the two spheroid types were visualized clearly and analyzed quantitatively by LIV and OCDSl imaging. For both spheroid types, structural corruptions and reduction of LIV and OCDSl were observed. These results may indicate different mechanisms of the drug action. The results suggest that dynamic OCT can be used to highlight drug response patterns and perform anti-cancer drug testing.
Open AccessLabel-free drug response evaluation of human derived tumor spheroids using three-dimensional dynamic optical coherence tomography
We demonstrate label-free drug response evaluations of human breast (MCF-7) and colon (HT-29) cancer spheroids via dynamic optical coherence tomography (OCT). The MCF-7 and HT-29 spheroids were treated with paclitaxel (PTX, or Taxol) and the active metabolite of irinotecan (SN-38), respectively. The drugs were applied using 0 (control), 0.1, 1, and 10 uM concentrations with treatment times of 1, 3, and 6 days. The samples were scanned using a repeated raster scan protocol and two dynamic OCT algorithms, logarithmic intensity variance (LIV) and late OCT correlation decay speed (OCDSl) analyses, were applied to visualize the tissue and cellular dynamics. Different drug response patterns of the two spheroid types were visualized clearly and analyzed quantitatively by LIV and OCDSl imaging. For both spheroid types, structural corruptions and reduction of LIV and OCDSl were observed. These results may indicate different mechanisms of the drug action. The results suggest that dynamic OCT can be used to highlight drug response patterns and perform anti-cancer drug testing.
- Open Access
- 5 October 2022
- Published by MDPI AG in Biomedicines
- Vol. 10 (10) , 2483
Plasma Exchange May Enhance Antitumor Effects by Removal of Soluble Programmed Death-Ligand 1 and Extracellular Vesicles: Preliminary Study
The antitumor effect of antibody-drug conjugates (ADC) is the main factor in achieving cures. Although the mechanism of tumor resistance to treatment is multifaceted, tumor-derived extracellular vesicles (T-EVs) have been implicated as contributing to the attenuation of ADC therapeutic efficacy. Thus, strategies to eliminate T-EVs are highly promising for overcoming drug resistance. Here we demonstrate plasma exchange therapy to remove T-EVs, decreasing their amount in vitro by 75%. Although trastuzumab emtansine (T-DM1) treatment alone was effective in our rat tumor model, the combination therapy of T-DM1 and T-EV filtration achieved early tumor shrinkage. Our results indicate that T-EV filtration plus ADC is a promising strategy for overcoming drug resistance.
- 5 October 2022
- Published by MDPI AG in Biomedicines
- Vol. 10 (10) , 2483
Open AccessPlasma Exchange May Enhance Antitumor Effects by Removal of Soluble Programmed Death-Ligand 1 and Extracellular Vesicles: Preliminary Study
The antitumor effect of antibody-drug conjugates (ADC) is the main factor in achieving cures. Although the mechanism of tumor resistance to treatment is multifaceted, tumor-derived extracellular vesicles (T-EVs) have been implicated as contributing to the attenuation of ADC therapeutic efficacy. Thus, strategies to eliminate T-EVs are highly promising for overcoming drug resistance. Here we demonstrate plasma exchange therapy to remove T-EVs, decreasing their amount in vitro by 75%. Although trastuzumab emtansine (T-DM1) treatment alone was effective in our rat tumor model, the combination therapy of T-DM1 and T-EV filtration achieved early tumor shrinkage. Our results indicate that T-EV filtration plus ADC is a promising strategy for overcoming drug resistance.
- 7 July 2020
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Robotics and Automation Letters
- Vol. PP (4) , 1
Detection and Control of Air Liquid Interface with an Open-Channel Microfluidic Chip for Circulating Tumor Cells Isolation from Human Whole Blood
We have proposed a bio-automation system to isolate and recover circulating tumor cells (CTCs) individually from whole blood. An open-channel microfluidic chip-based approach is used to isolate the CTCs. The proposed microfluidic chip design can form a stable air-liquid interface. CTCs are trapped by the gaps in between the pillars of the microfluidic chip due to capillary force associated with the meniscus of the air-liquid interface. We propose a chip design to stabilize air-liquid interface and sample flow speed. We introduce an image analysis algorithm to detect the position of the air-liquid interface. Using the visual feedback from the image analysis algorithm, a control system is proposed to control air-liquid interface position. We succeeded in stabilizing the flow speed, making it feasible for the isolation of 5 mL of whole blood to be completed within 30 min. We achieved an average of position error of air-liquid interface of 4 m with standard deviation of 7 m. We have confirmed that air-liquid interface position is a deciding factor for trapping area of CTCs. By controlling air-liquid interface position, we have achieved trapping CTCs in a narrow band with a high concentration.
- 7 July 2020
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Robotics and Automation Letters
- Vol. PP (4) , 1
Detection and Control of Air Liquid Interface with an Open-Channel Microfluidic Chip for Circulating Tumor Cells Isolation from Human Whole Blood
We have proposed a bio-automation system to isolate and recover circulating tumor cells (CTCs) individually from whole blood. An open-channel microfluidic chip-based approach is used to isolate the CTCs. The proposed microfluidic chip design can form a stable air-liquid interface. CTCs are trapped by the gaps in between the pillars of the microfluidic chip due to capillary force associated with the meniscus of the air-liquid interface. We propose a chip design to stabilize air-liquid interface and sample flow speed. We introduce an image analysis algorithm to detect the position of the air-liquid interface. Using the visual feedback from the image analysis algorithm, a control system is proposed to control air-liquid interface position. We succeeded in stabilizing the flow speed, making it feasible for the isolation of 5 mL of whole blood to be completed within 30 min. We achieved an average of position error of air-liquid interface of 4 m with standard deviation of 7 m. We have confirmed that air-liquid interface position is a deciding factor for trapping area of CTCs. By controlling air-liquid interface position, we have achieved trapping CTCs in a narrow band with a high concentration.
- 21 February 2020
- Published by SPIE-Intl Soc Optical Eng
- Vol. 11228, 112282C
Quantification of ex vivo tissue activity by short and long time-course analysis of multifunctional OCT signals
We present a new OCT-based tissue dynamics/subcellular motion analysis method to visualize tissue dynamics, where we increase the functionality of OCT to be sensitive for tissue dynamics by utilizing rapid-time-sequence analysis of OCT signals. These analysis includes log intensity variance (LIV) and OCT time-correlation analysis (OCT decorrelation speed; OCDS). In addition to LIV and OCDS methods, attenuation coefficient (AC), birefringence, and degree of polarization uniformity (DOPU) analysis were performed. These methods used to visualize and quantify long-term tissue dynamics degradation of different tissue types such as dissected mouse liver and tumor spheroids. These methods were quantitative, so the time-course tissue dynamics degradation has been not only visualized as an image, but also quantitative analysis of the dynamics degradation were performed.
- 21 February 2020
- Published by SPIE-Intl Soc Optical Eng
- Vol. 11228, 112282C
Quantification of ex vivo tissue activity by short and long time-course analysis of multifunctional OCT signals
We present a new OCT-based tissue dynamics/subcellular motion analysis method to visualize tissue dynamics, where we increase the functionality of OCT to be sensitive for tissue dynamics by utilizing rapid-time-sequence analysis of OCT signals. These analysis includes log intensity variance (LIV) and OCT time-correlation analysis (OCT decorrelation speed; OCDS). In addition to LIV and OCDS methods, attenuation coefficient (AC), birefringence, and degree of polarization uniformity (DOPU) analysis were performed. These methods used to visualize and quantify long-term tissue dynamics degradation of different tissue types such as dissected mouse liver and tumor spheroids. These methods were quantitative, so the time-course tissue dynamics degradation has been not only visualized as an image, but also quantitative analysis of the dynamics degradation were performed.
- Open Access
- 1 October 2017
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 492 (3) , 310-315
TIF1β is phosphorylated at serine 473 in colorectal tumor cells through p38 mitogen-activated protein kinase as an oxidative defense mechanism
- 1 October 2017
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 492 (3) , 310-315
Open AccessTIF1β is phosphorylated at serine 473 in colorectal tumor cells through p38 mitogen-activated protein kinase as an oxidative defense mechanism
- 11 April 2017
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 10 (474)
The transcription factor MAFK induces EMT and malignant progression of triple-negative breast cancer cells through its target GPNMB
Triple-negative breast cancer (TNBC) is particularly aggressive and difficult to treat. For example, the transforming growth factor–β (TGF-β) pathway is implicated in TNBC progression and metastasis, but its opposing role in tumor suppression in healthy tissues and early-stage lesions makes it a challenging target. Therefore, additional molecular characterization of TNBC may lead to improved patient prognosis by informing the development and optimum use of targeted therapies. We found that musculoaponeurotic fibrosarcoma (MAF) oncogene family protein K (MAFK), a member of the small MAF family of transcription factors that are induced by the TGF-β pathway, was abundant in human TNBC and aggressive mouse mammary tumor cell lines. MAFK promoted tumorigenic growth and metastasis by 4T1 cells when implanted subcutaneously in mice. Overexpression of MAFK in mouse breast epithelial NMuMG cells induced epithelial-mesenchymal transition (EMT) phenotypes and promoted tumor formation and invasion in mice. MAFK induced the expression of the gene encoding the transmembrane glycoprotein nmb (GPNMB). Similar to MAFK, GPNMB overexpression in NMuMG cells induced EMT, tumor formation, and invasion, in mice, whereas knockdown of MAFK in tumor cells before implantation suppressed tumor growth and progression. MAFK and GPNMB expression correlated with poor prognosis in TNBC patients. These findings suggest that MAFK and its target gene GPNMB play important roles in the malignant progression of TNBC cells, offering potentially new therapeutic targets for TNBC patients.
- 11 April 2017
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 10 (474)
The transcription factor MAFK induces EMT and malignant progression of triple-negative breast cancer cells through its target GPNMB
Triple-negative breast cancer (TNBC) is particularly aggressive and difficult to treat. For example, the transforming growth factor–β (TGF-β) pathway is implicated in TNBC progression and metastasis, but its opposing role in tumor suppression in healthy tissues and early-stage lesions makes it a challenging target. Therefore, additional molecular characterization of TNBC may lead to improved patient prognosis by informing the development and optimum use of targeted therapies. We found that musculoaponeurotic fibrosarcoma (MAF) oncogene family protein K (MAFK), a member of the small MAF family of transcription factors that are induced by the TGF-β pathway, was abundant in human TNBC and aggressive mouse mammary tumor cell lines. MAFK promoted tumorigenic growth and metastasis by 4T1 cells when implanted subcutaneously in mice. Overexpression of MAFK in mouse breast epithelial NMuMG cells induced epithelial-mesenchymal transition (EMT) phenotypes and promoted tumor formation and invasion in mice. MAFK induced the expression of the gene encoding the transmembrane glycoprotein nmb (GPNMB). Similar to MAFK, GPNMB overexpression in NMuMG cells induced EMT, tumor formation, and invasion, in mice, whereas knockdown of MAFK in tumor cells before implantation suppressed tumor growth and progression. MAFK and GPNMB expression correlated with poor prognosis in TNBC patients. These findings suggest that MAFK and its target gene GPNMB play important roles in the malignant progression of TNBC cells, offering potentially new therapeutic targets for TNBC patients.